3F8 is a murine IgG3[1] monoclonal antibody which binds to GD2.[2]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Mouse |
| Target | GD2 |
| Clinical data | |
| Routes of administration | intravenous |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
It has been used in the detection and treatment of neuroblastoma.[3] For imaging neuroblastoma, it is labelled with one of the radioisotopes iodine-124 and iodine-131.[4][5]
See also
editReferences
edit- ^ Kushner BH, Cheung NK (May 1989). "GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma". Blood. 73 (7): 1936–41. doi:10.1182/blood.V73.7.1936.1936. PMID 2653466.
- ^ "Sloan-Kettering - Neuroblastoma: 3F8 Monoclonal Antibody Therapy Q & A". Retrieved 2008-02-19.
- ^ Weinstein JL, Katzenstein HM, Cohn SL (1 June 2003). "Advances in the diagnosis and treatment of neuroblastoma". The Oncologist. 8 (3): 278–92. doi:10.1634/theoncologist.8-3-278. PMID 12773750. S2CID 20705441.
- ^ Yeh SD, Larson SM, Burch L, Kushner BH, Laquaglia M, Finn R, Cheung NK (May 1991). "Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities". Journal of Nuclear Medicine. 32 (5): 769–76. PMID 1902508.
- ^ Dauer LT, St Germain J, Williamson MJ, Zanzonico P, Modak S, Cheung NK, Divgi C (January 2007). "Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma". Health Physics. 92 (1): 33–9. doi:10.1097/01.HP.0000231583.32904.6c. PMID 17164597. S2CID 25792466.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |